Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) was downgraded by investment analysts at Vetr from a “strong-buy” rating to a “buy” rating in a report released on Monday. They currently have a $161.19 price target on the specialty pharmaceutical company’s stock. Vetr‘s price objective suggests a potential upside of 11.88% from the company’s current price.

A number of other research analysts also recently weighed in on JAZZ. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $187.00 target price on shares of Jazz Pharmaceuticals plc – in a research report on Tuesday, January 24th. Mizuho raised their target price on shares of Jazz Pharmaceuticals plc – from $127.00 to $152.00 and gave the company a “buy” rating in a research report on Tuesday, February 21st. Leerink Swann reaffirmed an “outperform” rating on shares of Jazz Pharmaceuticals plc – in a research report on Monday. Cowen and Company reaffirmed a “positive” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals plc – in a research report on Monday. Finally, Stifel Nicolaus decreased their target price on shares of Jazz Pharmaceuticals plc – from $200.00 to $190.00 and set a “buy” rating for the company in a research report on Wednesday, March 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $178.32.

Analyst Recommendations for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 6.91% on Monday, hitting $144.08. 1,753,586 shares of the stock were exchanged. The company has a 50-day moving average price of $131.85 and a 200-day moving average price of $119.55. The firm has a market capitalization of $8.61 billion, a PE ratio of 22.48 and a beta of 1.22. Jazz Pharmaceuticals plc – has a one year low of $95.80 and a one year high of $160.00.

Your IP Address:

In other news, COO Russell J. Cox sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $128.75, for a total transaction of $515,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction dated Wednesday, March 15th. The stock was sold at an average price of $137.89, for a total transaction of $27,578.00. Following the sale, the senior vice president now owns 22,762 shares of the company’s stock, valued at approximately $3,138,652.18. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,484 shares of company stock valued at $709,335. 3.90% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of JAZZ. World Asset Management Inc boosted its stake in Jazz Pharmaceuticals plc – by 15.0% in the third quarter. World Asset Management Inc now owns 1,667 shares of the specialty pharmaceutical company’s stock worth $203,000 after buying an additional 217 shares in the last quarter. Financial Architects Inc boosted its stake in Jazz Pharmaceuticals plc – by 192.5% in the third quarter. Financial Architects Inc now owns 5,166 shares of the specialty pharmaceutical company’s stock worth $627,000 after buying an additional 3,400 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Jazz Pharmaceuticals plc – by 1.9% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 8,762 shares of the specialty pharmaceutical company’s stock worth $1,064,000 after buying an additional 167 shares in the last quarter. Strs Ohio boosted its stake in Jazz Pharmaceuticals plc – by 21.0% in the third quarter. Strs Ohio now owns 215,160 shares of the specialty pharmaceutical company’s stock worth $26,137,000 after buying an additional 37,392 shares in the last quarter. Finally, Commonwealth Equity Services Inc boosted its stake in Jazz Pharmaceuticals plc – by 4.7% in the third quarter. Commonwealth Equity Services Inc now owns 5,948 shares of the specialty pharmaceutical company’s stock worth $723,000 after buying an additional 267 shares in the last quarter. Institutional investors own 88.56% of the company’s stock.

Jazz Pharmaceuticals plc – Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Stock Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related stocks with our FREE daily email newsletter.